Author's response to reviews

Title: Glycogen Synthase Kinase-3 Inhibition Disrupts Nuclear Factor-kappa B activity in Pancreatic Cancer, but Fails to Sensitize to Gemcitabine Chemotherapy

Authors:

Shadi Mamaghani (smamagha@uhnres.utoronto.ca)
Satish Patel (spatel@mshri.on.ca)
David W Hedley (david.hedley@uhn.on.ca)

Version: 3 Date: 31 March 2009

Author's response to reviews: see over
March 31, 2009

Dear Dr Marshall

Re: MS ID: 1667607122531825
“Glycogen Synthase Kinase-3 Inhibition Disrupts Nuclear Factor-kappaB Activity in Pancreatic Cancer, but Fails to Sensitize to Chemotherapy”, by Mamaghani et al.

We thank the reviewers and journal for completing the review of this manuscript. In response to comments by Dr Yip-Schneider, we have made the following additional changes:

1) Page 15, inserted “24 and 72hr data not shown” as requested.
2) We are confident with our results showing a relatively modest enhancement of gemcitabine effect following GSK-3 inhibition. However, we inserted an additional sentence at the end of the first paragraph, page 20: “Although the enhancement of gemcitabine toxicity following GSK-3 inhibition appears to be modest in vitro, we recognize that this does not exclude the potential for positive drug interaction in vivo, and this remains to be tested”, that we believe go part way to accommodating this reviewer’s viewpoint. We also modified the title slightly by inserting the word “gemcitabine” to make the point that the focus is on this particular chemotherapy agent.
3) We added β-catenin to the Figure 2 legend.

We also reviewed the format of the manuscript in order to bring this into journal style.

Yours sincerely

David Hedley